Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 10, No. 1, 15-21, January 2005; doi:10.1634/theoncologist.10-1-15
© 2005 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Buzdar, A.
Right arrow Articles by Macahilig, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Buzdar, A.
Right arrow Articles by Macahilig, C.

How Rapidly Do Oncologists Respond to Clinical Trial Data?

Aman Buzdara, Cynthia Macahiligb

a Department of Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA; b Market Certitude LLC, Morristown, New Jersey, USA

Correspondence: Aman Buzdar, M.D., Department of Medical Oncology, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA. Telephone: 713-792-2817; Fax: 713-794-4385; e-mail: abuzdar{at}mdanderson.org

In the era of evidence-based medicine, convincing clinical trial data should influence clinical practice if disseminated in an appropriate manner. Here we discuss the influence of clinical trial results from the Arimidex, Tamoxifen Alone or in Combination trial on the usage of tamoxifen and anastrozole in the treatment of postmenopausal women with hormone receptor-positive early breast cancer. Data were derived from structured interviews with practicing medical oncologists over a period of 28 months. The overall use of hormonal therapy was high and increasing over the period studied. Significant increases in the use of anastrozole as adjuvant hormonal therapy were accompanied by significant decreases in the use of tamoxifen. This culminated in the use of anastrozole surpassing tamoxifen use by the end of the study period, accounting for over 50% of hormonal therapy use for postmenopausal early breast cancer. This study suggests that the dissemination of key clinical data, accompanied by professional commentary and regulatory actions, can rapidly influence the clinical practice of medical oncologists.

Key Words. Early breast cancer • Hormonal • Postmenopausal • Adjuvant • Clinical trial




This article has been cited by other articles:


Home page
 J Oncol PractHome page
M. R. Green, M. Andrews, R. Leff, J. Willey, C. Allegra, A. Denes, J. Epstein, J. Jones, and L. Lokey
Adjuvant Therapy Choices in Patients With Resected Non-Small-Cell Lung Cancer: Correlation of Doctors' Treatment Plans and Relevant Phase III Trial Data
J. Oncol. Pract, July 1, 2005; 1(2): 37 - 42.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
Minerva
BMJ, January 22, 2005; 330(7484): 204 - 204.
[Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2005 by AlphaMed Press.
Advertisement